Impact of Glutathione-S-Transferases (GST) Polymorphisms and Hypermethylation of Relevant Genes on Risk of Prostate Cancer Biochemical Recurrence: A Meta-Analysis

Rui Chen¹, Shancheng Ren¹, Tong Meng², Josephine Aguilar³, Yinghao Sun¹*

¹ Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China, ² Department of Orthopedics, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, ³ Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States of America

Abstract

Introduction: Accurate prediction of the biochemical recurrence (BCR) is critical for patients after intended curative therapy like radical prostatectomy (RP) or definitive radiotherapy for prostate cancer. Glutathione-S-transferases polymorphisms as well as hypermethylation of GSTP1 and functional genes in carcinogenesis, including tumor suppression gene (APC), hormone receptor that regulates cell growth and differentiation gene (RARbeta) were reported to be associated with BCR. Nevertheless, the reported results are inconsistent. To evaluate the relationship between glutathione-S-transferases polymorphisms and hypermethylation of these genes and the risk of prostate cancer BCR, we carried out a meta-analysis of the published studies.

Methods and Materials: We performed a search in Medline, Embase and CNKI database with GST, APC, RARbeta in combination with single nucleotide polymorphism, hypermethylation, prostate cancer and recurrence. Languages were restricted to English and Chinese.

Results: Our study included 4 case-control studies and 7 cohort studies including 12 data sets and 3,037 prostate cancer patients. We confirmed that APC hypermethylation is associated with a modest hazard for biochemical recurrence after RP (HR = 1.85, 95%CI = 1.12–3.06). We also suggest GSTP1 polymorphism and CpG hypermethylation tested in serum are associated with BCR (HR = 1.94, 95%CI = 1.13–3.34). We also identified a possible association between GSTM1 null polymorphism and prostate cancer biochemical recurrence risk with borderline significance (HR = 1.29, 95%CI = 0.97–1.71).

Conclusion: To our knowledge, this is the first meta-analysis evaluating the relationship of polymorphisms and hypermethylation in GSTs and biochemical recurrence. GSTM1, GSTP1 polymorphisms and hypermethylation of GSTP1, APC may be potential biomarkers for the evaluation of the probability of BCR. Further studies are warranted to validate these findings in larger cohorts with longer follow-up.

Introduction

Prostate cancer (PCa) is the most commonly diagnosed cancer and the second leading cause of cancer-related deaths for men in the western world [1]. The unique biology of the disease poses significant challenges in the diagnosis and management of the disease. It is well recognized that widespread PSA screening has led to over-diagnosis and over-treatment of many men with indolent diseases [2,3]. Radical prostatectomy (RP) is often performed in localized PCa. Approximately 25–40% of patients will eventually experience biochemical recurrence (BCR) after RP in a longer follow-up period [4–6]. PSA concentration in serum of >0.2 ng/ml on one or two occasions after a previously undetectable level after prostatectomy is regarded as BCR [7] and it is the first sign of cancer recurrence. Patients with BCR have a much worse prognosis and often develop metastasis and can die of the disease [8,9]. So BCR have been used as an indicator of aggressive disease and immediate adjuvant treatment after RP may be beneficial for patients with high probability to develop BCR.

Several nomograms have been developed to predict subsequent risk of BCR after RP. They generally rely on known clinical and pathologic variables including PSA, Gleason score, clinical stage, and the number of positive and negative biopsy cores [4,10,11].
Unfortunately the collective prognostic value of these factors is unsatisfactory. Therefore, better biomarkers are urgently needed. The glutathione-S-transferases (GSTs) are phase II enzymes involved in detoxification of reactive oxygen species and environmental carcinogens, metabolism of steroid hormones and chemotherapeutic agents [12]. Extensive research has been carried out studying the relationship between GST single nucleotide polymorphisms (SNPs) and PCa susceptibility. A meta-analysis had indicated that GST polymorphisms may predict disease susceptibility and GSTM1 null allele may be associated with the lower risk of PCa observed for Asians [13]. However, they may not be associated with disease outcome and time to recurrence [14]. As for GSTT1 polymorphism, Cotignola J, et al. [15] indicated a 2.05-fold increase of risk of BCR however the result didn’t reach a statistical significant level and studies in other institutes failed to establish such a relationship [16,17]. Study carried out by Agalliu I, et al. [17] suggested a positive relationship between GSTM1 polymorphism and BCR while others did not comply with their findings [15,16]. The influence of GSTP1 polymorphism on BCR has also been shown to have inconsistent findings [15–19] (Table 1). However, these inconsistent results may due to the limited cases included and/or the potential differences in ethnicity across these studies. For instance, study by Cotignola, J, et al. [13] included only 105 patients; even for the largest studies, there are only 968 patients included [18]. So a meta-analysis of these studies is needed to yield more comprehensive understanding of GSTs polymorphisms on PCa prognosis.

Epigenetic changes in gene expression not caused by alterations in the primary sequence of the nucleotides of the gene. DNA hypermethylation is the most common epigenetic change and one of the most common molecular alterations in human cancer [19]. CpG dinucleotides can often be found in clusters called CpG islands in promoter regions. CpG islands of many genes, including tumor suppressor genes, are unmethylated in normal tissues but are methylated to varying degrees in multiple cancer types, causing silencing of gene transcription and inactivation of these tumors suppressor genes [19,20]. Promoter regions of several genes were found to be hypermethylated in PCs using methylation-specific PCR [21–27]. GSTP1 promoter hypermethylation represents the best currently available DNA-based biomarker for PCa because it is present in up to 90% of prostate cancer tissues and is only rarely present in benign prostate tissue [20]. Although GSTP1 hypermethylation was reported to be predictor of early biochemical recurrence following RP, the results from different studies vary vastly. For instance, in one study hypermethylated GSTP1 in patient serum is associated with a 4.4-fold increased risk of BCR [22]. Conversely, Bastian et al. [29] and Woodson et al. [23] did not find any correlation between GSTP1 hypermethylation and BCR. However, using GSTP1 CpG island hypermethylation alone may not be able to distinguish PCa from other cancers, since GSTP1 CpG island hypermethylation has been reported in other cancers [30]. What’s more, there are evidences to believe that GSTP1 methylation could trigger “epigenetic catastrophe” [31] which involves hypermethylation of associated genes including APC (a tumor suppression gene), and RAR-beta (tumor suppressor gene involved in cell cycle and apoptosis). Also, current available studies often investigate GSTP1 CpG island hypermethylation together with these genes. So we believe it is good practice to investigate these hypermethylated genes together with GSTP1. Currently available studies reported DNA methylation levels of the promoters of GSTP1, APC and RARb2 might be associated with higher risk of BCR with inconsistent results [18,19,21–24]. Since the inconsistent results may be due to relatively small sample sizes of individual studies, we carried out a meta-analysis of the available published studies.

Methods and Materials

Publication search

This work was approved by the Institutional Review Board of Changhai Hospital and was performed in accordance with the PRISMA 2009 Checklist for the conduct of meta-analysis (Checklist S1). We carried out a search in Medline, Embase, and CNKI database in Chinese with “glutathione-S-transferase(GST)”, “adenomatous polyposis coli (APC)”, “Retinoic acid receptor β (RARbeta OR RAR-beta OR RARβ)” in combination with “polymorphism OR single nucleotide polymorphisms OR SNPs”, “methylation OR hypermethylation”, “prostate cancer OR prostate neoplasms” and “recurrence OR relapse OR prognosis” (last search was updated on 2012-12-12). All terms were searched as MeSH terms or key words. We checked potentially relevant publications by examining their titles and abstracts, and all studies matching the eligible criteria were retrieved. Besides the database search, the bibliographies of the selected papers and reviews were also examined manually [26].

Criteria for inclusion and exclusion

Studies included in the meta-analysis must meet all of the following criteria: (a) evaluation of the glutathione-S-transferases polymorphisms, CpG hypermethylation and prostate cancer recurrence, (b) using a cohort or case-control design, (c) using a Cox proportional hazards model, (d) sufficient published data for estimating an hazard ratio (HR) with 95% confidence interval (CI), and (e) article was either in English or Chinese. Accordingly, the exclusion criteria were: (a) reviews and repeated literatures, (b) not offering the source of cases and controls and other essential information, and (c) not designed as case control or cohort studies. If studies had proper design for this meta-analysis but did not have enough data, an email was sent to the authors for further supplementary data [15,23,24] (Figure 1). In the searching period, 44 and 41 records were included in the PubMed and Embase. And one article was found through hand search of the citations of included articles [23]. 70 articles remains after duplication removed while 16 of them were excluded because they are review articles or written in other languages. We screened the remaining 54 articles and found that 15 of these studies focus on diagnosis of PCa and other aspects of these SNPs or hypermethylation rather than time to BCR (e.g. the proportion of more aggressive PCa or the chance of developing castration hormone refractory prostate cancer). In the remaining 23 studies for qualitative analysis, 12 articles failed to be eligible for quantitative synthesis because they didn’t provide the HRs and 95%CI for data extraction.

Data extraction

Data were independently abstracted by two investigators (RC and TM) using a standard protocol and data-collection form in accordance to the criteria stated above. Differences among evaluators were resolved by discussion and rereading with the third investigator (SR). The following information was extracted from each included study using a standardized data collection protocol (Table 1, Table 2): the surname of first author, year of publication, country, ethnicity, and number of cases in the cohort, number of cases with biochemical recurrence (BCR), design of the study, initial treatment, sample source, median time of follow-up, the minor allele frequency, the method used assessing methylation as well as median time to tumor recurrence. The definition of BCR in these included studies is slightly different. PSA concen-
| No. | Author, year | Country   | Ethnicity       | SNP/CpG hypermethylation | Total BCR | Non-BCR | Treatment | Sample | BCR (times of PSA>0.2) | Median follow-up (ys) | Median recurrence (ys) | Study design | Methylation test |
|-----|--------------|-----------|-----------------|--------------------------|-----------|---------|-----------|--------|-----------------------|----------------------|----------------------|--------------|------------------|
| 1   | Cotignola J, 2012 [15] | Argentina | Caucasian       | GSTM1,GSTT1,GSTP1        | 105       | 35      | RP        | Serum  | 1                     | 2,5                  | NA                   | Cohort       | -                |
| 2   | Nock NL, 2009 (1) [16] | USA       | Caucasian       | GSTM1,GSTT1,GSTP1        | 226       | 76      | Mixed (RP 67%) | Serum  | 2                     | 5                    | NA                   | Case-control | -                |
| 3   | Nock NL, 2009 (2) [16] | USA       | African American | GSTM1,GSTT1,GSTP1        | 168       |         | Serum     | 2      | 5                     | 5                    | NA                   | Case-control | -                |
| 4   | Agalliu I, 2006 [17] | USA       | Caucasian: 95%* | GSTM1,GSTT1,GSTP1        | 318       | 107     | Mixed (RP 68%) | Peripheral lymphocytes | 1                     | 96                   | NA           | Cohort           |
| 5   | Dluzniewski PJ, 2012 [18] | USA       | Caucasian       | GSTP1                    | 968       | 484     | 484       | RP     | 2,4                   | NA                   | NA                   | Case-control | -                |
| 6   | Liu L, 2011 [22]    | Canada    | Caucasian       | APC                      | 219       | NA      | NA        | Tissue | 1,2                   | 0.85                 | NA                   | Cohort       | qmPCR            |
| 7   | Ellinger J, 2008 (1) [23] | Germany   | Caucasian       | GSTP1                    | 122       | 24      | 98        | RP     | 1                     | 2.2                  | 0.85                 | Cohort       | reqPCR           |
| 8   | Ellinger J, 2008 (2) [24] | Germany   | Caucasian       | APC, RAR-beta            | 41        | 13      | 28        | RP     | 1                     | 1.7                  | 1.7                  | Cohort       | reqPCR           |
| 9   | Bastian PJ, 2005 [25] | USA       | Caucasian       | GSTP1, APC, RAR-beta     | 74        | 37      | 37        | RP     | 1                     | 2                    | 3                    | Case-control | reqPCR          |
| 10  | Rosenbaum E, 2005 [27] | USA       | Caucasian       | GSTP1, APC, RAR-beta     | 110       | 55      | 55        | RP     | 1                     | 9                    | 8                    | Cohort       | qmPCR            |
| 11  | Woodson K, 2006 [29] | USA       | Caucasian 82%** | GSTP1, RAR-beta          | 60        | 11      | 49        | RP     | 2                     | NA                   | NA                   | Cohort       | qmPCR            |

**BCR: biochemical recurrence; Non-BCR: patients without biochemical recurrence; qmPCR: Quantitative methylation-specific PCR; reqPCR: Restriction endonuclease quantitative PCR; NA: not available.

*Caucasian 91%, African-American 9% for BCR and Caucasian 97%, African-American 3% for Non-BCR.

**Caucasian 82%, African-American 18% for BCR and Caucasian 82%, African-American 12%, Asian 6% for Non-BCR.

doi:10.1371/journal.pone.0074775.t001
tion in serum of >0.2 ng/ml on one occasions after a previously undetectable level after prostatectomy is regarded as BCR in some studies while there are three studies define two consecutive PSA value of >0.2 ng/ml as BCR (Table 3). However, in clinic situation, we usually will let the patients take another PSA test in a short time to confirm previous finding so the influence between the two standards are not significant.

Most studies on GSTs polymorphisms uses multivariable Cox proportional hazards model. So we extract HR and 95%CI in the multivariable model that were adjusted for age, Gleason score, tumor stage at diagnosis, PSA screening history, smoking, and radical prostatectomy status as the multivariable model listed in Table 3. On the other hand, most studies on hypermethylation and PCa recurrence uses the univariate analysis and so that we extract HR and 95%CI in the univariate analysis or the closest to it (Table 3). So the analysis of these SNPs is mainly based on multivariable model and the analysis of hypermethylation changes is mainly based on univariable model. The ethnicity was categorized as Caucasian, African-American or mixed population. The percentage of each population in the mixed population has been specified in Table 1. In cases of publications by the same author, inquiries were sent to the author to clarify if there were overlaps of patients.

Statistical Analysis
The strength of the association between these polymorphisms or hypermethylation of promoter region and time to PCa biochemical recurrence was measured by HRs with 95% CIs. Odds ratios (ORs) or relative risks (RRs) measure only the number of events and take no account of when they occur are appropriate for measuring dichotomous outcomes, but less appropriate for analyzing time-to-event outcomes. The statistical significance of the summarized HR was determined by the Z-test. For GSTM1 and GSTT1 null polymorphisms, we estimated the impact of the “Null” genotype on time to recurrence, compared with the “Present” genotype. When it comes to GSTP1, the risk of biochemical recurrence evaluated is GSTP1 “AG vs. AA” and “GG vs. AA”, respectively. We didn’t evaluate other models (e.g. GG and AG vs. AA) because the data from included studies provides not sufficient data. As for hypermethylation of GSTP1 and other genes included, the risk of “promoter hypermethylation” compared with “not hypermethylation” was estimated. Homogeneity was evaluated by x2-based Q-test. If this test is rejected using a p-value cut point of 0.10 or less then there is sufficient evidence for the existence of heterogeneity and a lack of homogeneity. In this situation we utilize a random-effects model (the DerSimonian and Laird method) [32] which takes into account the between study variation. If p>0.1, it indicate homogeneity among these studies. There is a necessity to conduct the fixed-effect model (the Mantel-Haenszel method) [33] and we would also report the results of the random effects models as a form of sensitivity analysis to ensure that they are not substantially different. Sensitivity analysis was performed to assess the stability of the results. Begg’s funnel plot and Egger’s test were performed to assess the publication bias of literatures [34]; P<0.05 was considered statistically significant. All statistical tests for this meta-analysis were performed with STATA (version 11.0; Stata Corporation, College Station, TX).

Results
Study characteristics
All potentially eligible studies investigating the relationship between GST polymorphisms or the methylation of promoter
Table 2. Characteristics of patients involved in individual studies.

| No. | Author, year | Age at diagnosis(ys) | PSA at diagnosis(ng/ml) | Pathologic Gleason score (%) in cases |
|-----|--------------|----------------------|------------------------|--------------------------------------|
|     |              | BCR                  | Non-BCR                | BCR                                  | Non-BCR |
| 1   | Cotignola J,2012 [15] | 65 (49–74)          | 6.87 (0.77–29.80)     | <7% (15%)                             | 7% (15%) |
| 2   | Nock NL,2009 (1) [16] | 60.8±6.0             | 61.0±6.8               | 10.6±9.6                              | 6.0±4.3  |
| 3   | Nock NL,2009 (2) [16] | NA                   | NA                     | NA                                   | NA       |
| 4   | Agalli L,2006 [17]   | 57.5 ± 4.8           | 57.8 ± 4.4             | NA                                   | NA       |
| 5   | Dluzniewski PJ,2012 [18] | 58.9±6.2             | 59.0±5.9               | 12.0±9.5                              | 10.9±8.4 |
| 6   | Liu L, 2011 [22]     | 61.4(41.5–75.9)      | NA                     | NA                                   | 102(46.6) |
| 7   | Ellinger J,2008 (1) [23] | 66(49–79)            | <4: 6.6%; 4–10: 58.2%; | 78(63.9)                             | 24(19.7) |
| 8   | Ellinger J,2008 (2) [24] | 66(49-79)            | NA                     | NA                                   | 78 (63.9)% |
| 9   | Bastian P,2005 [25]  | 58.6(48–70)          | 59.7(43–71)            | 9.9(1.8–38)                          | 7.9(1.4–23.9) |
| 10  | Rosenbaum E,2005 [27] | 59.5(46–72)          | NA                     | 0                                    | 74(100) |
| 11  | Woodson K, 2006 [29] | 66.5 ± 3.5           | 64.6 ± 6.6             | 5.4±3.6                              | 8.1±12.2 |

BCR: biochemical recurrence; Non-BCR: patients without biochemical recurrence; NA: not available.

doi:10.1371/journal.pone.0074775.t002

region and prostate cancer recurrence were identified. During the extraction of data, 12 articles were excluded, because they did not provide essential data leaving 11 eligible articles including 12 data sets involving 3,037 prostate cancer patients [15–18,22–27] (Figure 1, Table 1). For GSTM1 and GSTT1 null polymorphisms, 817 patients in four groups were included from three studies [15–17] and for GSTP1 polymorphism, 1785 patients were included from five studies [15–18]. For GSTP1 hypermethylation five studies with 347 patients were included. For APC and RAR(bet), there are three studies included involving 293 and 144 patients, respectively. Several studies included patients of Caucasian descent while other studies included mixed races [17,26] and African-American population [16]. The ethnicity of the studies in mixed population is mainly Caucasian (95% and 82% respectively). Most articles studying polymorphisms used blood samples for genotyping assay except for one, which used tissue [18]. On the contrary, all studies on hypermethylation of gene promoter are genotyped with prostate cancer tissue except one, which used serum [25].

Test of homogeneity

There was significant heterogeneity across the studies of the GSTT1 null polymorphism, GSTP1 AG vs. AA polymorphism and GSTP1 hypermethylation. So a random-effect model was utilized to analyze these data and the source of heterogeneity was further explored in the sensitivity test. For other meta-analysis, the fixed-effect model was implied and the results of random-effect model have been compared as a type of sensitivity test.

Quantitative synthesis

For GSTM1 null polymorphism, none of the four included studies suggested a significant association with biochemical recurrence of prostate cancer. However, the meta-analysis in the fix model indicates that this polymorphism is associated with a 1.3-fold risk for biochemical recurrence with borderline significance (HR = 1.29, 95% CI = 0.97–1.71, p = 0.08) (Figure 2). So we may hypothesize that in a larger population GSTM1 null polymorphism may act as slight hazard for prostate cancer BCR.

The meta-analysis of GSTT1 null polymorphism did not show significant association among 4 studies with relatively large heterogeneity ($p = 0.08, I^2 = 0.57$). The results indicate GSTT1 null polymorphism to be a modest risk factor for biochemical recurrence (Figure 3).

The overall HR with its 95% CI showed no statistically significant association between the GSTP1 AG vs. AA polymorphism and time to biochemical recurrence using a random effect model (HR = 1.00, 95% CI = 0.68–1.47) (Figure 4). In the subgroup analysis by ethnicity, no statistically significant association was found among Caucasians either. On the contrary, GG vs. AA polymorphism is correlated with the risk of recurrence (Figure 5).

APC hypermethylation was associated with an increase risk of prostate cancer biochemical recurrence (HR = 1.23, 95% CI = 1.07–1.44) (Figure 6). Nevertheless, results showed no significant association between GSTP1 and RAR-beta promoter region hypermethylation and the recurrence after RP (Figure 7, Figure 8); GSTP1 and RAR-beta hypermethylation appears to be associated with a higher risk of biochemical recurrence (HR = 1.23 and 1.44 respectively) (Table 4).

Publication bias

Begg’s funnel plot and Egger’s test were performed to assess the publication bias of the currently available literature. The shapes of the funnel plot for the comparison of all the gene polymorphisms and promoter hypermethylation appeared symmetrical. Egger’s test was used to provide statistical evidence for funnel plot symmetry. The p-values of the Egger’s tests are 0.55 for GSTM1, 0.78 for SGTT1, 0.47 for GSTP1 AG vs. AA and 0.60 for GSTP1 GG vs. AA. The results did not suggest any evidence of publication bias (Figure S1).

Sensitivity analysis

For all gene variants, sensitivity analysis was performed by excluding one or more studies at one time. We estimated the sumarized effect in stratified analysis by race, sample type or...
| No. | Author, year | Gene        | SNP | Hypermethylation Status | HR and 95%CI | P     | Adjusted model | MAF            |
|-----|-------------|-------------|-----|--------------------------|--------------|-------|----------------|----------------|
| 1   | Cotignola J, 2012 [15] | M1 null vs. present | -   | -                        | 0.97 (0.47–2.01) | 0.94 | A              | 44.70%         |
| 2   | Nock NL, 2009 (1)[16] | M1 null vs. present | -   | -                        | 1.61 (0.89–2.96) | 0.11 | B              | 42.10%(BCR),38.70%(Non-BCR) |
| 3   | Nock NL, 2009 (2)[16] | M1 null vs. present | -   | -                        | 1.11 (0.44–2.41) | 0.95 | B              | 42.10%(BCR),38.70%(Non-BCR) |
| 4   | Agalliu I, 2006 [17] | M1 null vs. present | -   | -                        | 1.32 (0.89–1.96) | NA   | C              | 51.89%         |
| 1   | Cotignola J, 2012 [15] | T1 null vs. present | -   | -                        | 2.05 (0.92–4.54) | 0.08 | A              | 21.20%         |
| 2   | Nock NL, 2009 (1)[16] | T1 null vs. present | -   | -                        | 0.55 (0.21–1.40) | 0.2  | B              | 19.70%(BCR,21.10%(Non-BCR) |
| 3   | Nock NL, 2009 (2)[16] | T1 null vs. present | -   | -                        | 2.3 (1.01–5.18)  | 0.04 | B              | 19.70%(BCR,21.10%(Non-BCR) |
| 4   | Agalliu I, 2006 [17] | T1 null vs. present | -   | -                        | 1.09 (0.68–1.77) | NA   | D              | 16.67%         |
| 1   | Cotignola J, 2012 [15] | GSTP1 AG vs. AA | -   | -                        | 2.73 (0.89–8.38) | 0.08 | A              | 10.70%         |
| 2   | Nock NL, 2009 (1)[16] | GSTP1 AG vs. AA | -   | -                        | 0.96 (0.40–2.28) | 0.93 | B              | 21.10%(BCR,13.20%(Non-BCR) |
| 3   | Nock NL, 2009 (2)[16] | GSTP1 AG vs. AA | -   | -                        | 2.10 (0.66–6.67) | 0.21 | C              | 21.10%(BCR),13.20%(Non-BCR) |
| 4   | Agalliu I, 2006 [17] | GSTP1 AG vs. AA | -   | -                        | 0.91 (0.49–1.66) | NA   | D              | 10.38%         |
| 5   | Dluzniewski P, 2012 [18] | GSTP1 AG vs. AA | -   | -                        | 1.40 (1.06–1.86) | NA   | Univariate     | 39.58%         |
| 1   | Cotignola J, 2012 [15] | GSTP1 GG vs. AA | -   | -                        | 2.73 (0.89–8.38) | 0.08 | A              | 10.70%         |
| 2   | Nock NL, 2009 (1)[16] | GSTP1 GG vs. AA | -   | -                        | 0.96 (0.40–2.28) | 0.93 | B              | 21.10%(BCR,13.20%(Non-BCR) |
| 3   | Nock NL, 2009 (2)[16] | GSTP1 GG vs. AA | -   | -                        | 2.10 (0.66–6.67) | 0.21 | C              | 21.10%(BCR),13.20%(Non-BCR) |
| 4   | Agalliu I, 2006 [17] | GSTP1 GG vs. AA | -   | -                        | 0.91 (0.49–1.66) | NA   | D              | 10.38%         |
| 5   | Dluzniewski P, 2012 [18] | GSTP1 GG vs. AA | -   | -                        | 1.35 (0.84–2.16) | NA   | Univariate     | 11.73%         |
| 7   | Ellinger J, 2008 (1) [23] | - | GSTP1 hypermethylation | -   | -                        | 1.25 (0.58–2.69) | 0.58 | Univariate     | -              |
| 8   | Ellinger J, 2008 (2) [24] | - | GSTP1 hypermethylation | -   | -                        | 1.02 (0.96–1.08) | 0.5  | Univariate     | -              |
| 9   | Bastian P, 2005 [25] | - | GSTP1 hypermethylation | -   | -                        | 0.34 (0.13–0.88) | 0.03 | Margin, age, lymph - node status |
| 10  | Rosenbaum E, 2005 [27] | - | GSTP1 hypermethylation | -   | -                        | 0.34 (0.13–0.88) | 0.03 | Univariate     | -              |
| 11  | Woodson K, 2006 [29] | - | APC hypermethylation | -   | -                        | 5.31 (0.63–45.07) | 0.13 | Univariate     | -              |
| 6   | Liu L, 2011 [22] | - | APC hypermethylation | -   | -                        | 2.22 (0.78–6.32) | 0.14 | Margin, age, Gleason score, tumor stage |
| 8   | Ellinger J, 2008 (1) [23] | - | APC hypermethylation | -   | -                        | 1.47 (0.03–72.67) | 0.85 | Univariate     | -              |
| 10  | Rosenbaum E, 2005 [27] | - | APC hypermethylation | -   | -                        | 1.60 (0.80–3.19) | 0.18 | Univariate     | -              |
| 9   | Ellinger J, 2008 (2) [24] | - | RAR(beta) hypermethylation | -   | -                        | 1.00 (1.00–1.00) | 0.34 | Univariate     | -              |
| 10  | Rosenbaum E, 2005 [27] | - | RAR(beta) hypermethylation | -   | -                        | 1.22 (0.59–2.52) | 0.59 | Univariate     | -              |
| 11  | Woodson K, 2006 [29] | - | RAR(beta) hypermethylation | -   | -                        | 3.34 (0.66–17.29) | 0.14 | Univariate     | -              |

A: Adjusted for age, margin, Gleason score, tumor stage, PSA, family history of PCa, smoking status.
B: Adjusted for age, tumor stage, tumour grade, PSA, smoking status.
C: Adjusted for age, Gleason score, tumor stage, PSA, family history of PCa, smoking status, and RP status.
MAF: minor allele frequency; BCR: biochemical recurrence; Non-BCR: patients without biochemical recurrence; NA: not available.

There are two groups of patients in study by Nock et al. The data set of Nock NL, 2009 (1) is consist of Caucasian population and Nock NL, 2009 (2) data set is consist of African-Americans.

doi:10.1371/journal.pone.0074775.t003
method to test methylation. Results of stratified analysis have been listed in Table 5.

For GSTM1 null polymorphism, when we perform stratified analysis in studies in Caucasian, the summarized results indicated a moderate hazard for GSTM1 null polymorphism at a borderline

Figure 2. Results of meta-analysis of GSTM1 null polymorphism.
doi:10.1371/journal.pone.0074775.g002

For GSTM1 null polymorphism, when we perform stratified analysis in studies in Caucasian, the summarized results indicated a moderate hazard for GSTM1 null polymorphism at a borderline

Figure 3. Results of meta-analysis of GSTT1 null polymorphism.
doi:10.1371/journal.pone.0074775.g003
significance (HR = 1.31, 95%CI = 0.98–1.78, p = 0.07). As for GSTT1 null polymorphism, results of any stratification failed to yield a significant association with prostate cancer BCR. GSTP1 GG polymorphism showed a 1.5-fold risk of BCR over GSTP1 AA when the analysis is confined to studies using serum sample (HR = 1.50, 95%CI = 1.05–2.15, p = 0.03). Subgroup analysis of

Figure 4. Results of meta-analysis of GSTP1 AG vs. AA polymorphism.
doi:10.1371/journal.pone.0074775.g004

Figure 5. Results of meta-analysis of GSTP1 GG vs. AA polymorphism.
doi:10.1371/journal.pone.0074775.g005
studies in Caucasians has achieved similar results with a lower HR and a borderline significance similar with results of the overall analysis (p = 0.14 and p = 0.09, respectively). GSTP1 hypermethylation status was not significant associated with BCR in the overall analysis, however, when we confine the analysis to those carried out using serum samples with restriction endonuclease quantitative PCR to test methylation level, hypermethylation act as a significant risk factor for BCR (HR = 1.94, 95%CI = 1.13–3.34, p = 0.02). When we use the random-effect model for those studies with a low heterogeneity, the results are quite close to the data we got from the fixed-effect model (Table 4). Thus we may have more evidence to believe it is appropriate to imply the fixed-effect model.

### Discussion

In current standard of care, biochemical recurrence after RP serves as a trigger point for further treatment; therefore any biomarker that is correlated with biochemical recurrence would be a valuable tool for the clinical management of the disease. Polymorphism of GSTs has been extensively studied unveiling a possible association with prostate cancer susceptibility and risk of biochemical recurrence. This meta-analysis supports the

### Table 4. Main Results of meta-analysis.

| No. | Gene | SNP/Epigenetic | No. of studies | No. of patients | Model | Test of association | Test of heterogeneity |
|-----|------|----------------|----------------|----------------|-------|---------------------|----------------------|
|     |      |                |                |                |       | HR (95% CI)         | P-value  |
| 1   | GSTM1| Null vs. present | 4              | 817            | Fixed | 1.29 (0.97, 1.71)*  | 0.08  |
| 2   | GSTT1| Null vs. present | 4              | 817            | Random | 1.31 (0.76, 2.24) | 0.33  |
| 3   | GSTP1| AG vs. AA       | 5              | 1785           | Random | 1.00 (0.68, 1.47) | 0.99  |
| 4   | GSTP1| GG vs. AA       | 5              | 1785           | Fixed | 1.27 (0.97, 1.67)*  | 0.09  |
| 5   | GSTP1| Hypermethylation vs. Non-hypermethylation | 5 | 347 | Random | 1.23 (0.66, 2.29) | 0.52  |
| 6   | APC  | Hypermethylation vs. Non-hypermethylation | 3 | 293 | Fixed | 1.85 (1.12, 3.06)* | 0.02  |
| 7   | RAR(beta) | Hypermethylation vs. Non-hypermethylation | 3 | 144 | Fixed | 1.44 (0.74, 2.80)* | 0.28  |

*HRs and 95% CIs in the random-effect model are: 1.29(0.97, 1.71), 1.33(0.94, 1.9), 1.85(1.12, 3.06), and 1.53(0.67, 3.49) for GSTM1, GSTP1 GG vs. AA, APC and RAR(beta), respectively.

**Figure 6. Results of meta-analysis of APC promoter hypermethylation.**

doi:10.1371/journal.pone.0074775.g006
association with GSTM1 and GSTP1 polymorphism with an increased risk of BCR with borderline significance. The proteins GSTM1 and GSTP1 encode are known to have an important impact in modification of some enzymes. These enzymes may have function in the detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins and products of oxidative stress, by conjugation with glutathione [35]. The polymorphisms of GSTM1 and GSTP1 may influence the function of these enzymes in carcinogenicity of prostate. Additionally, hypermethylation status has been used as effective biomarkers in some pioneering studies with satisfactory results [36]. In one study included in the meta-analysis, quantitative
methylation assessment of a multiplex panel of markers, consisting of APC, HOXD3 and TGFβ2, outperforms any single currently available biomarker [22]. In another study, APC exhibits very high NPV (negative predictive value) in men with initial negative biopsy but high suspicion for cancer suggesting that methylation markers have the potential to eliminate up to 30% of re-biopsies after an initial negative biopsy [36].

We put special emphasis on GSTP1, because its methylation has been shown to occur early in high-grade prostatic intraepithelial neoplasia (HGPIN), suggesting the possibility of using GSTP1 to detect very early stage of recurrence [37]. Moreover, some researchers have hypothesized that GSTP1 methylation could trigger “epigenetic catastrophe” [31] which involves hypermethylation of additional genes including APC, and RAR-beta. Further investigations should target more genes including EFB41L3, HOXD3, CD44, PTGS2 and other genes that may be involved in this hypermethylation process [37].

In this meta-analysis, we suggest APC hypermethylation can pose a modest hazard for BCR after RP. The results also indicated that GSTP1 hypermethylation tested in serum may be an effective indicator for BCR after RP. GSTP1 GG polymorphism tested in serum has been illustrated to poses a hazard to BCR in overall population with a borderline significance and significant results were yield in the studies using serum as test sample. Taking the limited sample size of included studies, we may believe that if more cases are enrolled this effect may be more significant.

In the 11 studies included, 4 are designed as case-control studies and 7 are cohort studies. All the case-control studies have selected the proper controls and the cohort studies are also well-designed. Furthermore, nine studies indicated a median time follow-up ranging from 1.7 to 9 years and two studies failed to offer the median time follow-up. However, the median time to BCR after RP ranged from 1.7 to 8 years and in 7 studies this data was not reported, suggesting the possibility of insufficient follow-up. In the publication search period we excluded articles in languages other than English and Chinese. When considering studies of other language, only one study in German was qualified; however, there was inadequate data in the abstract to be included.

In interpreting the results, some cautions should be applied. First, the heterogeneity and small sample size may have distorted this meta-analysis. For instance, a few published studies lacked the essential data required and not all the articles set RP as an initial treatment, making the effects of different treatments on the time to BCR and rate of BCR unclear. Further studies should discriminate between various treatments and focus on the BCR after a single therapeutic modality such as RP. Similarly, there is some heterogeneity in the aspect of ethnicity, as some of the studies investigated mixed population. Secondly, currently available studies failed to investigate the relationship between race and gene polymorphisms and methylation. Subsequent studies should concentrate on exploring the genetic and epigenetic differences that exist among the different races. Thirdly, although available genetic data suggest an increased risk for BCR with APC, GSTM1 and GSTP1 promoter methylation, we still lack the knowledge of their gene-environment interactions. Further studies are warranted to confirm these findings.

**Conclusion**

In conclusion, to our knowledge this is the first meta-analysis evaluating the polymorphisms and methylation in GSTs and biochemical recurrence. We confirmed that APC CpG hypermethylation poses a modest hazard for BCR after RP. We also suggest GSTP1 polymorphism and CpG hypermethylation tested in serum are probably associated with BCR. There are the potential implications of these SNPs and epigenetic change for evaluation of the probability of BCR. Further studies are warranted to validate these findings in a larger cohort with a longer follow-up.
Supporting Information

Figure S1  Funnel plot of publication bias.
(DOCX)

Checklist S1  PRISMA 2009 Checklist.
(DOC)

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1309–1320.
3. Andreule GL, Crawford ED, Grubb RL. (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 15 years of follow-up. J Natl Cancer Inst 104: 123–132.
4. Han M, Partin AW, Zahrak M, Piantadosi S, Epstein JJ, et al. (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169: 517–523.
5. Busch J, Stephan C, Herold A, Erber B, Krennmueller C, et al. (2012) Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience. BJU Int 110: E256–260.
6. Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, et al. (2008) A nonmonotonic relationship between prostate cancer risk and smoking: a pooled analysis of 32 population-based case-control studies. Cancer Causes Control 20: 1915–1926.
7. Freedland SJ, Sutter ME, Dorey F, Aronson WJ (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Cancer 112: 1254–1263.
8. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey JJ, et al. (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433–439.
9. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591–1597.
10. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr., Dotan ZA, et al. (2006) Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Urol 179: 715–717.
11. Chun FK, Karakiewicz PI, Huland H, Gerbing RJ (2007) Role of nomograms for prostate cancer in 2007. World J Urol 25: 131–142.
12. Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45: 51–88.
13. Wei B, Xu Z, Zhou Y, Sun Z, Jin ZX, et al. (2012) Association of GSTM1 null allele with prostate cancer risk: evidence from 36 case-control studies. PLoS One 7: e46902.
14. Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, et al. (2009) Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 18: 1659–1662.
15. Cotignola J, Leonard RB, Shahabi A, Acuna AD, Stern MC, et al. (2012) Glutathione-S-transferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Prostate Cancer Prostatic Dis 15: 216–222.
16. Nock NL, Beck C, Nelder-Duhas C, Beebe-Dimmer J, Rundle A, et al. (2009) Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity. Cancer Causes Control 20: 1915–1926.
17. Aguilera L, Lin DW, Salinas CA, Feng Z, Stanford JL (2006) Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate 66: 1535–1541.
18. Bluzièreski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, et al. (2012) Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 21: 1774–1780.
19. Ph V, Cassenet O, Roupret M (2010) Methylated genes as potential biomarkers in prostate cancer. BJU Int 105: 1364–1370.
20. Chiam K, Ricciardelli C, Bianco-Miotto T (2012) Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett.
21. Mahapatra S, Kler EW, Young CY, Sun Z, Jimenez RE, et al. (2012) Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18: 2892–2895.
22. Liu L, Kron KJ, Pethe VV, Desmatredevhi N, Nesbit ME, et al. (2011) Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 129: 2454–2462.
23. Ellinger J, Haam K, Hekamp LC, Kahl P, Butter R, et al. (2008) CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68: 42–49.
24. Ellinger J, Bastian FJ, Jurgan T, Biermann K, Kahl P, et al. (2008) CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urol Log 71: 161–167.
25. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, et al. (2005) Preoperative serum DNA GSTPI CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Cancer Clin Res 11: 4037–4043.
26. Woodson K, O’Reilly KJ, Ward DE, Walter J, Hamon J, et al. (2006) CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 1: 183–186.
27. Rosenbaum E, Hoque MO, Cohen Y, Zahrak M, Eisenberger MA, et al. (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clinical Cancer Research 11: 8321–8329.
28. Ph V, Cassenet O, Roupret M (2010) Methylated genes as potential biomarkers in prostate cancer. BJU International 105: 1364–1370.
29. Bastian PJ, Ellinger J, Hekamp LC, Kahl P, Muller SC, et al. (2007) Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 51: 665–674; discussion 674.
30. Esteller M, Cern PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61: 6225–6229.
31. Yegnasubramanian S, Kovalski J, Gonzalez ML, Zahrak M, Plantadosi S, et al. (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64: 1973–1986.
32. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
33. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
34. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
35. Guer A, Haidinger G, Hinteregger S, Bernhofer G, Schatzl G, et al. (2001) Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer 95: 154–158.
36. Trucck B, Bestman MJ, Mangold LA, Bigley JW, Epstein JL, et al. (2012) Evaluation of GSTPI and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 110: 56–62.
37. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, et al. (2004) A quantitative promoter methylation profile of prostate cancer. Cancer Clin Res 10: 8472–8478.